Cite

HARVARD Citation

    Ma, D. et al. (2018). Exploiting mitochondrial and oxidative vulnerabilities with a synthetic analog of pancratistatin in combination with piperlongumine for cancer therapy. FASEB journal. 32 (1), pp. 417-430. [Online]. 
  
Back to record